Cao, MD
Bruce Cao, Germantown, MD US
Patent application number | Description | Published |
---|---|---|
20140212490 | TABLET FOR PULSED DELIVERY - A pharmaceutical tablet comprising an immediate release portion containing an active ingredient and a delayed release portion, wherein the delayed release portion comprises an enteric-coated layer and within the enteric-coated layer there is at least one member selected from the group consisting of enteric-coated microparticle dosage forms containing an active ingredient and enteric-coated mini-tablet dosage forms containing an active ingredient, is disclosed. | 07-31-2014 |
Haiming Cao, Bathesda, MD US
Patent application number | Description | Published |
---|---|---|
20110213032 | FATTY ACID C16: 1N7-PALMITOLEATE A LIPOKINE AND BIOMARKER FOR METABOLIC STATUS - The present invention provides for a novel lipokine, C16:1n7-palmitoleate, which also serves as a biomarker for metabolic status. More specifically, a low concentration of C16:1n7-palmitoleate in the free acid component of the serum indicates a risk of metabolic disease, and that de novo lipogenesis should be stimulated. Additionally, administering C16:1n7-palmitoleate to a subject (via nutraceutical or other means), positively impacts lipid metabolism. | 09-01-2011 |
Haiming Cao, Bethesda, MD US
Patent application number | Description | Published |
---|---|---|
20120134998 | SECRETED AP2 AND METHODS OF INHIBITING SAME - A method of reducing a symptom of a clinical disorder characterized by aberrantly elevated circulating aP2 is carried out by administering to a subject an inhibitor of secreted aP2, secretion of aP2, or a serum aP2 blocking agent. For example, glucose intolerance is reduced following administration of such an inhibitor or agent. Exemplary compositions inhibit cellular secretion of aP2 or bind to circulating aP2, thereby reducing the level or activity of aP2 in blood or serum. | 05-31-2012 |
20130267599 | USE OF TRANS-PALMITOLEATE IN IDENTIFYING AND TREATING METABOLIC DISEASE - The present invention provides for a novel lipokine, trans-C16:1n7-palmitoleate, which also serves as a biomarker for metabolic status. More specifically, low concentrations of trans-C16:1n7-palmitoleate the serum indicates a risk of metabolic disease. Additionally, administering trans C16:1n7-palmitoleate to a subject (via pharmaceutical, nutraceutical, or other means), positively impacts glucose metabolism. | 10-10-2013 |
Jianjing Cao, Ellicott City, MD US
Patent application number | Description | Published |
---|---|---|
20140296249 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | 10-02-2014 |
Jianjing Cao, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20100267737 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | 10-21-2010 |
Kan Cao, Bowie, MD US
Patent application number | Description | Published |
---|---|---|
20140024698 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA - Provided are methods of treatment in subjects having progeroid diseases and related conditions which rely upon LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin. | 01-23-2014 |
Liang Cao, Bethesda, MD US
Patent application number | Description | Published |
---|---|---|
20090087906 | NOVEL CELL-BASED ASSAYS FOR G-PROTEIN-COUPLED RECEPTOR-MEDIATED ACTIVITIES - Disclosed are compositions and methods for their use, such as in identifying G-protein-coupled receptors, ligands and compounds that modulate the activities of G-protein-coupled receptors. The compositions and methods employ cyclic nucleotide-gated channels and fluorescence dyes in detecting changes of intracellular cAMP levels in response to the stimulation of G-protein-coupled receptors. Activation of the G-protein-coupled receptors can be detected in a variety of assays, including cell-based imaging assays with fluorescence microscopes and high throughput assays with multi-well plates and fluorescence plate readers. | 04-02-2009 |
20090192088 | Vascular Endothelial Growth Factor 2 - Disclosed is a human VEGF2 polypeptide and DNA(RNA) encoding such VEGF2 polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist against such polypeptide. Such polypeptides may be combined with a suitable pharmaceutical carrier or diluent to provide diagnostic, therapeutic and/or prophylactic effects against various diseases. Also provided are methods of using the antibodies and antagonists to inhibit the action of VEGF2 for therapeutic purposes. | 07-30-2009 |
20100143360 | HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR 2 - Disclosed is a human VEGF2 polypeptide and DNA(RNA) encoding such VEGF2 polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist against such polypeptide. Also disclosed is a method of using such polypeptide for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antagonists to inhibit tumor growth, inflammation and to treat diabetic retinopathy, rheumatoid arthritis and psoriasis. Diagnostic methods for detecting mutations in the VEGF2 coding sequence and alterations in the concentration of VEGF2 protein in a sample derived from a host are also disclosed. | 06-10-2010 |
Shanjin Cao, Rockville, MD US
Patent application number | Description | Published |
---|---|---|
20100143353 | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (lgG) AND METHODS OF USING THE SAME - Polypeptides comprising at least a first and second Fc fragment of IgG that can be used to induce a stimulated cell to produce the anti-inflammatory cytokine Interleukin-10 and methods of using the same are disclosed herein. | 06-10-2010 |
20120283417 | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME - Polypeptides comprising at least a first and second Fc fragment of IgG that can be used to induce a stimulated cell to produce the anti-inflammatory cytokine Interleukin-10 and methods of using the same are disclosed herein. | 11-08-2012 |
Weidong Cao, N. Potomac, MD US
Patent application number | Description | Published |
---|---|---|
20160051985 | SYSTEM AND METHOD FOR SERIAL PROCESSING OF MULTIPLE NUCLEIC ACID ASSAYS - The present invention relates to systems and methods for the real time processing of nucleic acid during polymerase chain reaction (PCR) and thermal melt applications. According to an aspect of the invention, a system for the rapid serial processing of multiple nucleic acid assays is provided. In one embodiment, the system includes, but is not limited to: a microfluidic cartridge having microfluidic (flow-through) channels, a fluorescence imaging system, a temperature measurement and control system; a pressure measurement and control system for applying variable pneumatic pressures to the microfluidic cartridge; a storage device for holding multiple reagents (e.g., a well-plate); a liquid handling system comprising at least one robotic pipettor for aspirating, mixing, and dispensing reagent mixtures to the microfluidic cartridge; systems for data storage, processing, and output; and a system controller to coordinate the various devices and functions. | 02-25-2016 |
Weidong Cao, Rockville, MD US
Patent application number | Description | Published |
---|---|---|
20090111149 | METHOD OF REDUCING CROSS-CONTAMINATION IN CONTINUOUS AMPLIFICATION REACTIONS IN A CHANNEL - The present invention relates to a method for reducing cross-contamination in continuous amplification reactions in channels of microfluidic devices. More specifically, the present invention relates to the use of specific materials continuously flowing in the channels to reduce adsorption of MgCl | 04-30-2009 |
20090112481 | HIGH-RESOLUTION MELTING ANALYSIS - The present invention relates to methods and systems for the analysis of the dissociation behavior of nucleic acids and the identification of nucleic acids. In one aspect, methods and systems are disclosed for resolving a denaturation curve of a sample containing a first and second nucleic acid into a resolved denaturation curve for the first nucleic acid and a resolved denuration curve for the second nucleic acid. | 04-30-2009 |
20090130746 | MICROCHANNEL SURFACE COATING - The present invention relates to a method for improving the efficiency of biochemical reactions in channels of microfluidic devices. More specifically, the present invention relates to the use of chitosan or a chitosan derivative for coating channel surfaces to reduce non-specific adsorption of reagents to microfluidic channels. This reduction of non-specific adsorption improves the efficiency and reproducibility of the reaction, e.g., amplification reactions, such as PCR, and reduces cross-contamination. | 05-21-2009 |
20090215124 | Nucleic acid isolation methods and materials and devices thereof - The present invention relates to methods for purifying nucleic acid from a sample using mild conditions that do not affect the chemical integrity of the nucleic acid. The method comprises contacting the sample with an matrix entrapped chitosan solid phase which is able to bind the nucleic acids at a first pH, and then extracting the nucleic acid from the solid phase by using an elution solvent at a second pH. | 08-27-2009 |
20100021910 | Methods and Systems for Microfluidic DNA Sample Preparation - The present invention relates to methods and systems for microfluidic DNA sample preparation. More specifically, embodiments of the present invention relate to methods and systems for the isolation of DNA from patient samples on a microfluidic device and use of the DNA for downstream processing, such as performing amplification reactions and thermal melt analysis on the microfluidic device. | 01-28-2010 |
20100167279 | UNSYMMETRICAL CYANINE DYES FOR HIGH RESOLUTION NUCLEIC ACID MELTING ANALYSIS - The present invention relates to novel unsymmetrical cyanine dyes and to methods of performing nucleic acid analysis in the presence of such dyes. More specifically, the present invention relates to novel unsymmetrical cyanine dyes that have high affinity to double-stranded nucleic acids and that do not inhibit amplification reactions, particularly the polymerase chain reaction (PCR). | 07-01-2010 |
20100233687 | METHOD AND SYSTEM FOR TEMPERATURE CORRECTION IN THERMAL MELT ANALYSIS - The present invention relates to methods and systems for temperature correction in thermal melt analysis. More specifically, embodiments of the invention relate to the correction of the melting temperature (T | 09-16-2010 |
20130217022 | Methods and Systems for Microfluidic DNA Sample Preparation - The present invention relates to methods and systems for microfluidic DNA sample preparation. More specifically, embodiments of the present invention relate to methods and systems for the isolation of DNA from patient samples on a microfluidic device and use of the DNA for downstream processing, such as performing amplification reactions and thermal melt analysis on the microfluidic device. | 08-22-2013 |
Xu Cao, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20110256557 | IDENTIFYING PARATHYROID HORMONE AGONISTS AND ANTAGONISTS - Provided herein are methods of screening for an agent that is a PTH agonist or antagonist. For example, provided is a method of screening for an agent that is a PTH agonist or antagonist, the method comprising contacting a cell with LRP6 and the agent to be screened, wherein the cell comprises a PTH1R, and determining the level of LRP6 binding to the PTH1R. An increased level of LRP6 binding to the PTH1R compared to a control indicates the agent is a PTH agonist. A decreased level of LRP6 binding to the PTH1R compared to a control indicates the agent is a PTH antagonist. Also provided are methods of treating a skeletal disorder in a subject, wherein the skeletal disorder is characterized by proliferative bone growth or reduced bone density. | 10-20-2011 |
20120294871 | MODULATION OF GPCR-MEDIATED CAMP PRODUCTION THROUGH LRP6 AND ITS THERAPEUTIC APPLICATION - The present invention relates to low-density lipoprotein receptor related protein 6 (LRP6). More specifically, the present invention relates to targeting of LRP6 to modulate Gα | 11-22-2012 |
20150139909 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OSTEOARTHRITIS - The present invention relates to the field of osteoarthritis. More specifically, the present invention provides compositions and methods useful for treating or preventing osteoarthritis. In one embodiment, a method for treating or preventing osteoarthritis in a patient comprises the step of administering to the patient a therapeutically effective amount of a transforming growth factor beta (TGF-beta) inhibitor. | 05-21-2015 |